Navigation Links
Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference

Evidence Base for MEDIHONEY(TM) Dressings Continues To Grow

PRINCETON, N.J., March 6 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that seven abstracts detailing the clinical usage of its newly released MEDIHONEY Wound & Burn Dressings with Active Leptospermum Honey were accepted for presentation at the upcoming annual Symposium on Advanced Wound Care conference, held this year between April 24 - 27 in San Diego, CA. Additionally, the company has announced that two of the abstracts will be presented as oral presentations to a general assembly of the conference attendees.

Chairman and CEO Ed Quilty said, "MEDIHONEY dressings continue to receive positive levels of acceptance by clinicians worldwide and has become the most talked about treatment for hard-to-heal wounds in many forums. Having several abstracts related to MEDIHONEY dressing accepted in the largest annual international conference of its kind validates our very high expectations, and helps to further our goal of advancing wound care by uncovering technological innovations, empowering caregivers, and focusing on unmet patient needs."

The abstracts include the following:

"The Importance of Medical Grade Honey Rather than Table Honey in the Treatment of Wounds"; Cooper RA, Jenkins L, Rowlands R. (oral presentation)

"The Inhibition of Biofilms of Pseudomonas Aeruginosa with Manuka Honey"; Cooper RA, Jenkins L, Rowlands R. (oral presentation)

"Manuka Honey Alginate Wound Dressing Facilitates Healing Of Chronic Diabetic Lower Extremity Ulcerations"; Robert Frykberg, DPM, MPH, Arthur Tallis, DPM, Cherese Thomas-Ramoutar, DPM, Edward Tierney, DPM.

"Comparison of Honey-Impregnated Calcium Alginate Dressings to Non-Impregnated Calcium Alginate Dressings on Wound Healing"; Catherine T. Milne, APRN, MSN, CWOCN; Connecticut Clinical Nursing Associates, LLC, Bristol Hospital Wound, Ostomy, Lymphedema Center, Bristol, CT.

"It Looks Like Honey. It Smells Like Honey. Yes, It Is Honey!"; Becky Strilko, RN, BSN, CWOCN, APN, Christine Barkauskas, RN, BA, CWOCN, APN, Andrea Mcintosh, RN, BSN, CWOCN, APN, Noreen Reaney, RN, BSN, Wound Ostomy and Continence Student, Provena Saint Joseph Medical Center, Joliet, IL.

"The Influence of Catalase on the Antibacterial Activity of Honey"; Cooper RA, Jenkins L, Rowlands R.

"The Effects of a Leptospermum Honey Dressing on Methicillin-Resistant Staphylococcus Aureus (MRSA) Biofilms Using a Well Established Porcine Wound Infection model"; Stephen C. Davis, Yan Rivas, Joel Gil, Roberto Perez, Jose Valdes, Robert Kirsner, Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large-scale randomized controlled studies on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at

About the SAWC

The SAWC is the Annual Symposium for the Association for Advancement of Wound Care and the Wound Healing Society Meeting. It is an annual conference specifically dedicated to the wounds and wound-related issues. The largest conference of its kind drawing attendees from all over the world, the meeting is an informational hub for multidisciplinary wound care clinicians and researchers. The SAWC/WHS comprises four days of educational sessions, meetings, interactive events, and social gatherings, including a pre- and post-conference.

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

Contact: Derma Sciences Inc Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO

(609) 514-4744 Brian Kennedy (media)

(212) 691-8087

SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Founding Father of Modern Cosmetic Dermatology Seeks to Warn Public of Misrepresented Data and Inappropriate Use of Botox
2. DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Companys Melanoma Advisory Board
3. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
4. Hyaluronic Acid Dermal Filler Market Skyrockets
5. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
6. 1st EMEA application filed for product using innovative intradermal microinjection system BD Soluvia
7. PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
8. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
9. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
10. Leading Cosmetic Dermatologist, Peter G. Ballas II MD, Retains Kay Renz Public Relations to Promote his Practice and New Skincare Line
11. Prominent Cosmetic Dermatologist and Author Joins
Post Your Comments:
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary ... Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 as ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology: